X4 Pharmaceuticals (XFOR) Reports In-Line Q2 EPS

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.74), in-line with the analyst estimate of ($0.74).

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'